Inovio Pharmaceuticals, Inc. Form 8-K (Nov. 8, 2022)

Summary

Inovio Pharmaceuticals, Inc. reported in this Form 8-K, under Item 2.02, that on November 8, 2022 it issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022, furnished as Exhibit 99.1. The report states that the information in Item 2.02 and Exhibit 99.1 is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. Item 9.01 lists the November 8, 2022 press release and the cover page interactive data file as exhibits. Peter Kies, Chief Financial Officer, signed on November 8, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2022

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-14888 | 33-0969592
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
660 W. Germantown Pike , Suite 110
Plymouth Meeting , PA 19462
(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.001 par value | INO | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 | Results of Operations and Financial Condition.

On November 8, 2022, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 | Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number
99.1 | Press Release, dated November 8, 2022
104 | Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.
Date: November 8, 2022 | By: | /s/ Peter Kies
Peter Kies
Chief Financial Officer

File and source

File

SEC_INO_8-K_filed2022-11-08_0001193125-22-280159.htm

Size

25,692 bytes

SHA-256

e086b2ac81fdd11bbd20b1fe70b90411c7b655d0bc41b4135ae92e5baf54dfc0

Our copy

SEC_INO_8-K_filed2022-11-08_0001193125-22-280159.htm

Original

www.sec.gov